Advertisement

Letter to the editor: Should we stop using post-contrast sequences in the follow-up MRI of patients with multiple sclerosis?

Published:September 14, 2022DOI:https://doi.org/10.1016/j.jns.2022.120421
      We read with great interest the article by Gentili et al. entitled “Impact of post-contrast MRI in the definition of active multiple sclerosis”[
      • Gentili L.
      • Capuano R.
      • Gaetani L.
      • Fiacca A.
      • Bisecco A.
      • d’Ambrosio A.
      • Mancini A.
      • Guercini G.
      • Tedeschi G.
      • Parnetti L.
      • Gallo A.
      • Di Filippo M.
      Impact of post-contrast MRI in the definition of active multiple sclerosis.
      ]. The authors found that the contribution of post-contrast sequences in the classification of active multiple sclerosis, according to the 2013 classification [
      • Lublin F.D.
      • Reingold S.C.
      • Cohen J.A.
      • Cutter G.R.
      • Sørensen P.S.
      • Thompson A.J.
      • Wolinsky J.S.
      • Balcer L.J.
      • Banwell B.
      • Barkhof F.
      • Bebo Jr., B.
      • Calabresi P.A.
      • Clanet M.
      • Comi G.
      • Fox R.J.
      • Freedman M.S.
      • Goodman A.D.
      • Inglese M.
      • Kappos L.
      • Polman C.H.
      Defining the clinical course of multiple sclerosis: the 2013 revisions.
      ], was only marginal (less than 2%).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Altay E.E.
        • Fisher E.
        • Jones S.E.
        • Hara-Cleaver C.
        • Lee J.-C.
        • Rudick R.A.
        Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.
        JAMA Neurol. 2013; 70: 338https://doi.org/10.1001/2013.jamaneurol.211
        • Brasil
        Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. PORTARIA CONJUNTA N° 7, DE 3 DE JULHO DE 2022. Protocolo Clínico e Diretrizes Terapêuticas da Esclerose Múltipla.
        2022
        • Burke L.M.B.
        • Ramalho M.
        • AlObaidy M.
        • Chang E.
        • Jay M.
        • Semelka R.C.
        Self-reported gadolinium toxicity: a survey of patients with chronic symptoms.
        Magn. Reson. Imaging. 2016; 34: 1078-1080
        • Gasperini C.
        • Prosperini L.
        • Rovira À.
        • Tintoré M.
        • Sastre-Garriga J.
        • Tortorella C.
        • Haggiag S.
        • Galgani S.
        • Capra R.
        • Pozzilli C.
        • Montalban X.
        • Río J.
        Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score.
        Eur. J. Neurol. 2021; 28: 2533-2542
        • Gentili L.
        • Capuano R.
        • Gaetani L.
        • Fiacca A.
        • Bisecco A.
        • d’Ambrosio A.
        • Mancini A.
        • Guercini G.
        • Tedeschi G.
        • Parnetti L.
        • Gallo A.
        • Di Filippo M.
        Impact of post-contrast MRI in the definition of active multiple sclerosis.
        J. Neurol. Sci. 2022; 440120338
        • Gulani V.
        • Calamante F.
        • Shellock F.G.
        • Kanal E.
        • Reeder S.B.
        • International Society for Magnetic Resonance in Medicine
        Gadolinium deposition in the brain: summary of evidence and recommendations.
        Lancet Neurol. 2017; 16: 564-570
        • Lublin F.D.
        • Reingold S.C.
        • Cohen J.A.
        • Cutter G.R.
        • Sørensen P.S.
        • Thompson A.J.
        • Wolinsky J.S.
        • Balcer L.J.
        • Banwell B.
        • Barkhof F.
        • Bebo Jr., B.
        • Calabresi P.A.
        • Clanet M.
        • Comi G.
        • Fox R.J.
        • Freedman M.S.
        • Goodman A.D.
        • Inglese M.
        • Kappos L.
        • Polman C.H.
        Defining the clinical course of multiple sclerosis: the 2013 revisions.
        Neurology. 2014; 83: 278-286
        • Robert P.
        • Lehericy S.
        • Grand S.
        • Violas X.
        • Fretellier N.
        • Idée J.-M.
        • Ballet S.
        • Corot C.
        T1-weighted Hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents.
        Investig. Radiol. 2015; 50: 473-480
        • Sadigh G.
        • Saindane A.M.
        • Waldman A.D.
        • Lava N.S.
        • Hu R.
        Comparison of unenhanced and gadolinium-enhanced imaging in multiple sclerosis: is contrast needed for routine follow-up MRI?.
        AJNR Am. J. Neuroradiol. 2019; 40: 1476-1480